Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with...
Year: 2023
Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress
Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s...
Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer
Study Reveals 50% of respondents in leadership roles catch incidents of field reps using unapproved content, but a continuous learning...
Graduate program in population and health systems management receives award for innovation in education
First-of-its-kind collaboration between Boise State, a leading public university and HFMA, a major professional association, is recognized by the Commission...
Bicycle Health and Wellpath Team Up to Provide Opioid Use Disorder Treatment to Federal Bureau of Prisons
The leading virtual Opioid Use Disorder treatment provider will fill gaps in care for formerly incarcerated patients struggling with opioid...
22nd Century Group (Nasdaq: XXII) to Announce Fourth Quarter and Full Year 2022 Results on March 9, 2023
BUFFALO, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to...
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current...
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Company Launches a New Educational Campaign For ProvidersMALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
International Myeloma Foundation (IMF) Launches #MYelomaSTORY Campaign for Myeloma Action Month in March 2023
STUDIO CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action...
Science 37 to Present at the Cowen 43rd Annual Health Care Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today...
BioLife Sciences, Inc. (OTC:PK BLFE) (BioLife or the Company) is Pleased to Announce the Release of the Prototype of the Company’s Copper-Infused Microfiber Towels for Q2 of the Fiscal Year
HENDERSON, NV, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – The Copper-Infused Microfiber Towels are copper-variations of traditional microfiber...
Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to...
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
TEL AVIV, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical...
Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of...
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical...
Patent Application Published for PharmAla Biotech’s MDMA Analogs
Patent covers 6 novel compositions of matter, which PharmAla has been studying in preclinical testing for over a yearVANCOUVER, British...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
Following the IND clearance, the Company is advancing into a Phase 1 clinical studyPotentially addressing most common subtypes of adenocarcinoma...
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s...